Evogene

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evogene reports revenue growth and strategic collaborations driving future prospects

Evogene's Q1 2024 performance showed revenue growth, decreased losses, and strategic milestones achieved by key subsidiaries.
The company's strengths lie in innovative collaborations, a unique CPB platform, and successful revenue-driving partnerships.
Challenges include financial management, operational execution, and logistical considerations for seed supply.
Opportunities for growth stem from promising future achievements, strategic partnerships, and market differentiation through innovation.

Evogene reports revenue surge and promising developments in key segments

Evogene demonstrated strong revenue growth in the first half of 2024 and made progress in reducing losses, reflecting improving financial performance.
Casterra's expanding market reach and revenue growth opportunities, coupled with Biomica's promising trial results, position Evogene well for future growth.
While facing challenges in achieving profitability and managing cash flow, Evogene's focus on operational efficiency and market expansion presents avenues for sustainable growth.

Evogene reports Q3 revenue decline but anticipates growth opportunities

Evogene's Q3 2024 performance reflected a decline in revenues but improved cost management, with a focus on enhancing cash reserves.
The company's strengths lie in upcoming revenue growth, strategic collaborations, and plans to fortify its financial position.
Challenges include market uncertainties, operational losses, and addressing investor concerns for sustained growth and profitability.
Opportunities exist for Evogene to capitalize on its achievements, explore new avenues, and drive value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evogene (EVGN) delivered earnings and revenue surprises of -42.86% and 46.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Evogene (EVGN) Reports Q1 Loss, Lags Revenue Estimates

Conference call and webcast: today, May 26, 2022, 9:00 am ET REHOVOT, Israel , May 26, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the first quarter ended March 31, 2022.

Evogene Reports First Quarter 2022 Financial Results

REHOVOT, Israel , May 23, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

Biomica to Present at the ASCO 2022 Annual Meeting

REHOVOT, Israel , May 16, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.

Biomica to Present at the 2022 Digestive Disease Week (DDW) Conference

Corteva Inc

Given wheat global shortages and high prices, Lavie foresees continued strong demand for its bio-inoculant result ™  and plans increased production for 2023 growing season REHOVOT, Israel , May 11, 2022 /PRNewswire/ -- Lavie Bio Ltd., a subsidiary of Evogene Ltd.

Lavie Bio Announces Successful Product Launch of its Bio-Inoculant result™ for the 2022 Spring Wheat Growing Season

REHOVOT, Israel , May 10, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the first quarter of 2022 on Thursday, May 26, 2022.

Evogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2022

The research will be focused on developing new treatments for Inflammatory Bowel Disease (IBD) REHOVOT, Israel, April 13, 2022 /PRNewswire/ -- Biomica Ltd. (Biomica), an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica Announces Agreement with Sheba Medical Center for Joint Microbiome Clinical Research

Evogene acts as a computational biology technology hub; $50M market cap, $54M cash, 5 subsidiaries (4 of which are valuable). The article discusses subsidiaries Biomica, Lavie Bio and AgPlenus.

Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus

REHOVOT, Israel , March 14, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will be attending the Jefferies Virtual Synthetic Biology Week which is taking place between March 21-25, 2022.

Evogene to Present at the Jefferies Virtual Synthetic Biology Week on March 23, 2022

Evogene Ltd (EVGN) CEO Ofer Haviv on Q4 2021 Results - Earnings Call Transcript

REHOVOT, Israel, March 10, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the fourth quarter and full year of 2021, ended December 31, 2021.

Evogene Reports Fourth Quarter and Full Year 2021 Financial Results

REHOVOT, Israel, March 7, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will be attending the World Agri-Tech Innovation Summit from March 22-23, 2022 in San Francisco.

Evogene to Attend to World Agri-Tech Innovation Summit from March 22-23, 2022

REHOVOT, Israel , March 3, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will present at the 34th Annual ROTH Conference being held both virtually and in-person in Dana Point, California on March 13-15, 2022.

Evogene to Attend the 34th Annual ROTH Investor Conference in Dana Point California Between March 13-15, 2022

Evogene is a computational biology company that acts a technology hub, creating life science divisions and subsidiaries.

Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)

Intercure Ltd

Tilray Brands

cbdMD Inc

Clever Leaves Holdings Inc

Flora Growth Corp

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make our way through 2022.

These Pot Stocks Made Major International Moves This Week

REHOVOT, Israel, Feb. 16, 2022 /PRNewswire/ -- Canonic Ltd., focused on the development of medical-grade cannabis products and a wholly-owned subsidiary of Evogene Ltd.

Canonic Announces Professor Itamar Grotto Joining its Board of Directors

Computational biology company Evogene Ltd. (NASDAQ:EVGN)  will release its financial results for the full year and fourth quarter of 2021 on March 10, 2022.

Computational Biology Company Evogene Confirms Earnings Results Release Date

REHOVOT, Israel, Feb. 15, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the full year and fourth quarter of 2021 on Thursday, March 10, 2022.

Evogene Financial Results and Earnings Announcement Schedule for the Full Year and Fourth Quarter of 2021

REHOVOT, Israel, Feb. 7, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ-GM: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments announced today that it will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 25th at 9:00 Eastern.

Evogene to Present at Aegis Virtual Conference

Canopy Growth

HEXO Corp

Neptune Wellness Solutions Inc.

PepsiCo

Dr. Reddy's Labs

22nd Century Group

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is shaping up as we kick off 2022.

These Pot Stocks Went Wild This Week

Medical grade cannabis products developer Canonic Ltd. and a subsidiary of Evogene Ltd.

Evogene's Canonic Ships First Batch Of Unique Cannabis Varieties To Europe

REHOVOT, Israel, Jan. 31, 2022 /PRNewswire/ -- Canonic Ltd., focused on the development of medical grade cannabis products and a wholly-owned subsidiary of Evogene Ltd.

Canonic Announces Shipment of its Cannabis Varieties to Europe

Agrify

GrowGeneration Corp

IM Cannabis Corp

Urban-gro

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is shaping up as we dive into 2022.

Cannabis Stock News: S(potify) Makes its Move

REHOVOT, Israel, Jan. 19, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today it is participating in Edison Group's Open House Event, scheduled to take place virtually this month.

Evogene to Participate in Edison Group's Global Healthcare "Open House" Virtual Conference from January 25-27th, 2022

Medical grade cannabis products developer Canonic Ltd., a subsidiary of Evogene Ltd.

News for Evogene Stock (EVGN)